Introduction {#s1}
============

Sepsis is a clinical syndrome, affecting ∼19 million individuals per year worldwide, characterized by a maladaptive host response with ensuing life-threatening organ dysfunction resulting from infection ([@B43]; [@B57]). Cardiac involvement frequently complicates to sepsis, which, if severe, can lead to death ([@B20]; [@B30]; [@B56]). Characteristically, early studies indicate cardiac dysfunction in adequately volume-resuscitated septic patients with increased end-diastolic volume index and decreased ejection fraction, and these acute changes in ejection fraction and end-diastolic volume index, although sustained for several days, were reversible ([@B58]; [@B4]; [@B39]). More recently, studies in cellular levels, isolated heart studies, animal models *in vivo*, and in human studies, have clearly established decreased contractility and impaired myocardial compliance as major factors that cause myocardial dysfunction in sepsis ([@B32]; [@B30]).

The bacterial endotoxin lipopolysaccharide (LPS), which is a component of the outer membrane of Gram-negative bacteremia, has been regarded as a main culprit responsible for cardiac dysfunction in sepsis ([@B2]). Mechanistically, LPS associates with its receptor toll-like receptor 4 (TLR4) through the help of LPS-binding protein CD14 and, subsequently, results in the production of inflammatory cytokines, such as TNFα, IL-1β, and IL-18, which might directly disturb cardiac function ([@B24]; [@B42]; [@B66]). Although tremendous efforts have been made during the last decades, no specific therapy for sepsis-induced cardiomyopathy exists ([@B57]). Therefore, there is urgent need of innovative therapeutic options for sepsis-induced cardiomyopathy, which is essential for reducing the mortality of sepsis.

Hydrogen gas (H~2~), a medical gas that has anti-oxidant, anti-apoptotic, and anti-inflammatory properties ([@B34]; [@B62]; [@B65]; [@B64]; [@B26]; [@B63]), has been reported to improve sepsis-induced organ dysfunction, such as lung ([@B41]; [@B27]; [@B60]; [@B19]; [@B29]; [@B13]; [@B11]), liver ([@B48]; [@B22]), and bowel ([@B44]). Recent studies have also indicated that H~2~ has strong cardiovascular activities ([@B69]). For example, intraperitoneal injection of H~2~ can improve isoproterenol (ISO)-induced cardiac hypertrophy *in vivo* ([@B70]; [@B67]) and inhibit vascular hypertrophy induced by abdominal aortic coarctation *in vivo* ([@B72]). H~2~-rich medium suppresses ISO-induced H9c2 cardiomyocytes hypertrophy and angiotensin II-induced vascular smooth muscle cells proliferation and migration *in vitro* ([@B72]). However, the effects of H~2~ intraperitoneal injection on sepsis-induced cardiomyopathy and the molecular mechanisms remain unclear. The aims of this study are, therefore, to determine the effect of H~2~ intraperitoneal injection on LPS-induced cardiac dysfunction *in vivo* and the effect of H~2~-rich medium on LPS-induced H9c2 cardiomyocytes injury *in vitro*, as well as to identify the molecular mechanisms that may be involved in this process.

Materials and Methods {#s2}
=====================

Drugs, Antibodies, and ELISA Kits {#s2_1}
---------------------------------

LPS (cat no. L2880, Sigma-Aldrich; MerekKGaA, Darmstadt, Germany) was dissolved in normal saline (1 mg/ml), under sterile conditions immediately prior intraperitoneal injection, and dissolved in double distilled water (1 mg/ml) as for cell culture study. H~2~ (99.999%; Guang Zhou Guang Qi Gas Co., Ltd., Guangzhou, China) was stored in a seamless steel gas cylinder. H~2~ was injected into a vacuumed aseptic soft plastic infusion bag (100 ml; CR Double-Crane Pharmaceuticals Co., Ltd, Anhui, China) under sterile conditions immediately prior to intraperitoneal injection for animal study. For cell culture study, the same vacuumed bag was injected with 20-ml Dulbecco's modified Eagle medium (DMEM; Gibco, New York City, NY, USA), which was supplemented with 100 U/ml penicillin/streptomycin (Hyclone); then, the bag with DMEM was bubbling by H~2~ until this bag was full of H~2~ with no dead volume. The bag was maintained at 4°C for \>6 h prior to use, and the concentration of H~2~ was measured as our previously described ([@B72]; [@B67]).

The antibodies against extracellular signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, p38, p-p38, c-Jun NH2-terminal kinase (JNK), p-JNK, NF-κB p65, and Histone H3 and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were from Cell Signaling Technology (Danvers, MA, USA). The antibody against TLR4 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

The mouse TNFα, IL-1β Enzyme Linked Immunosorbent Assay (ELISA) kits were from R&D Systems (Minneapolis, USA). The mouse IL-18 ELISA kit was from Medical & Biological Laboratories CO., LTD. (Nagoya, Japan).

Animal Model of LPS-Induced Cardiac Dysfunction and Treatment Protocol {#s2_2}
----------------------------------------------------------------------

Male C57BL/6J mice (8 to 10 weeks of age) were used in this study. All animals were housed in a temperature-controlled animal facility with a 12-h light--dark cycle and allowed to obtain rodent chow and water *ad libitum*. All animals received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society of Medical Research and the Guide for the Care and Use of Laboratory Animals published by the NIH (8^th^ Edition, Revised 2011) ([@B40]). The Institutional Animal Care and Use Committee (Zhongshan School of Medicine, Sun Yat-sen University) approved all animal procedures.

Mice were randomly assigned to four groups: Control (Con) group (*n* = 10), LPS group (*n* = 10), LPS plus H~2~ group (*n* = 10), and H~2~ group (*n* = 10). In LPS plus H~2~ group and H~2~ group, H~2~ (99.999%) was given at the dose of 1 ml per 100 g/day by intraperitoneal injection as our previously described for 4 days ([@B70]; [@B67]). On the fourth, LPS was given to LPS group and LPS plus H~2~ group by intraperitoneal injection (5 mg/1,000g) as previously revealed ([@B14]), Con group was treated with saline. Moreover, H~2~ was given 0.5 h before LPS injection in LPS plus H~2~ group. Transthoracic echocardiography was performed with a Vevo-2100 high-frequency ultrasound system (VisualSonics Inc., Toronto, Canada) to assess left ventricular ejection fraction (EF%), fractional shortening (FS%), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular mass average weight (LV mass AW), and LV mass AW (Corrected, = 0.8 × LV mass AW) 6 h post-LPS administration as previously described ([@B10]; [@B33]; [@B21]; [@B54]).

Cell Culture and Treatment {#s2_3}
--------------------------

H~2~-rich medium was prepared as previously described ([@B67]). H9c2 cardiomyocytes were grown in DMEM containing 5.5-mM glucose ([@B67]). Cells were serum starved for 18 h in DMEM containing 1% FBS and then treated with H~2~-rich medium for 30 min before LPS; finally, the medium was added 1 µg/ml LPS. The expression or activation of kinases, NF-κB, TLR4, and cytokines were examined after 6 h of LPS challenge.

The Enzyme-Linked Immunosorbent Assay {#s2_4}
-------------------------------------

The levels of TNFα, IL-18, and IL-1β in serum of mice were quantified by the commercial ELISA kits following manufacturer's instructions. The plates were read on a TECAN infinite F200 Plate Reader, measuring absorbance at 450 nm.

Quantitative Real-Time PCR (qRT-PCR) {#s2_5}
------------------------------------

Total mRNA was extracted from H9c2 cardiomyocytes using TRIZol reagent (Invitrogen) as previously described ([@B70]). The oligo (dT) primers with the Transcriptor First Strand cDNA Synthesis Kit (PrimeScript^™^ RT Master Mix, Takara) were used to synthesize cDNA. qRT-PCR was performed using SYBR green (SYBR^®^ Premix Ex Taq^™^II, Takara) on a BIO-RAD CFX96 Touch^™^ Real-time PCR Detection System. GAPDH was used as an internal control. The relative expression level of target genes was calculated using the 2^−ΔΔCt^ method. The primers for qRT-PCR are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Sequence of primers used for quantitative real-time PCR (qRT-PCR).

  -----------------------------------------------------------
  Genes       Species   Sequence (5' → 3')
  ----------- --------- -------------------------------------
  **TNFα**    Rat       (Forward)-AAATGGGCTCCCTCTCATCAGTTC\
                        (Reverse)-TCTGCTTGGTGGTTTGCTACGAC

  **IL-1β**   Rat       (Forward)-TCGTGCTGTCTGACCCATGT\
                        (Reverse)-ACAAAGCTCATGGAGAATACCACTT

  **IL-18**   Rat       (Forward)-ACGGAGCATAAATGACCAAGTTC\
                        (Reverse)-TCTGGGATTCGTTGGCTGTT

  **ANP**     Rat       (Forward)-GGGAAGTCAACCCGTCTCA\
                        (Reverse)-GGCTCCAATCCTGTCAATCC

  **BNP**     Rat       (Forward)-CTCCAGAACAATCCACGATG\
                        (Reverse)-ACAGCCCAAGCGACTGACT

  **GAPDH**   Rat       (Forward)-CCAAGGTCATCCATGACAACTT\
                        (Reverse)-AGGGGCCATCCACAGTCTT
  -----------------------------------------------------------

Histological and Morphological Analyses {#s2_6}
---------------------------------------

Hearts were harvested for observing histological and morphological alterations by hematoxylin and eosin (H&E) staining and Masson's trichrome staining as previously revealed ([@B70]; [@B61]).

Western Blotting {#s2_7}
----------------

Western blotting was performed as we have previously described ([@B67]). The nuclear protein were isolated by the NE-PER^™^ Nuclear and Cytoplasmic Extraction Reagent Kit (Thermo Fisher Scientific, Waltham, MA, USA). The proteins were transferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA), which were incubated with primary and secondary antibodies by standard techniques. The enhanced chemiluminescence (ChemiDoc XRS+ System, Bio-Rad, Hercules, CA, USA) was used to accomplish immunodetection.

Statistical Analysis {#s2_8}
--------------------

Data are expressed as mean ± SD. Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by Bonferroni's *post hoc* test. A value of *P* \< 0.05 was considered as significantly different.

Results {#s3}
=======

H~2~ Alleviates LPS-Induced Cardiac Dysfunction {#s3_1}
-----------------------------------------------

We attempted to use intraperitoneal injection of H~2~, to test whether H~2~ can suppress LPS-induced cardiac dysfunction. As previously described ([@B15]), 6 h after LPS challenge, mice exhibited cardiac dysfunction compared with the control group, as indicated by decreasing percent fractional shortening (FS%) and percent ejection fraction (EF%) and increasing LVESD, while left ventricular end-diastolic diameter (LVEDD) was not affected ([**Figures 1A--E**](#f1){ref-type="fig"}). H~2~ injection alleviated the impaired cardiac function by LPS, as evidenced by increasing FS% and EF% and decreasing LVESD ([**Figures 1A--E**](#f1){ref-type="fig"}). Therefore, intraperitoneal injection of H~2~ can improve LPS-induced cardiac dysfunction.

![H~2~ protects against lipopolysaccharide (LPS)-induced cardiac dysfunction. **(A)** Representative M-mode echocardiographic images at 6 h after LPS injection. **(B--E)** Quantification of left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), EF%, and FS% by echocardiography at 6 h after LPS injection (*n* = 10). \*\**P* \< 0.01 vs Control, ^\#\#^ *P* \< 0.01 vs LPS.](fphar-10-00865-g001){#f1}

The Effect of H~2~ on Left Ventricular Structure in the Challenge of LPS {#s3_2}
------------------------------------------------------------------------

LPS can upregulate pathologic hypertrophy marker ANP and BNP and induce cellular hypertrophy in H9c2 cardiomyocytes ([@B28]). In our study, the upregulation of mRNA levels of ANP and BNP by LPS was suppressed by H~2~-rich medium pretreatment ([**Figure 2A**](#f2){ref-type="fig"}). LPS slightly increased LV mass AW and LV mass AW (Corrected), and the mean of LV mass AW and LV mass AW (Corrected) were lower in H~2~ plus LPS group than that in LPS group, although there was no statistical difference between groups ([**Figure 2B**](#f2){ref-type="fig"}). Similar to the increased in LVESD in LPS group ([**Figure 1C**](#f1){ref-type="fig"}), H&E staining showed that LPS induced left and right ventricular cavities enlargement, decreased the thickness of interventricular septum, and H~2~ improves these phenotype ([**Figure 2C**](#f2){ref-type="fig"}). Moreover, no obvious cardiac fibrosis was induced by LPS, H~2~, and H~2~ plus LPS as determined by Masson's trichrome staining ([**Figure 2D**](#f2){ref-type="fig"}). As previously discussed ([@B27]; [@B60]), the formation of lung edema and the influx of immune-competent cells into the lung tissue by LPS were reduced by H~2~ ([**Figure 2E**](#f2){ref-type="fig"}). Collectively, these data suggested that H~2~ has the potential ability to improve LPS-induced left ventricular structure injury in these mice.

![The effect of H~2~ on left ventricular structure in the challenge of LPS. **(A)** Quantification of the mRNA levels of ANP and BNP *in vitro*, GAPDH was used as a loading control (*n* = 3). **(B)** LV mass AW and LV mass AW (Corrected) were calculated by Vevo LAB analysis software from Vevo-2100 high-frequency ultrasound system (*n* = 10). **(C)** Hematoxylin and eosin (H&E) staining for myocardium, 20×. **(D)** Masson's trichrome staining for myocardium. **(E)** H&E staining for lung. \*p \< 0.05 vs Control, \*\**P* \< 0.01 vs Control, ^\#^ *P* \< 0.05 vs LPS.](fphar-10-00865-g002){#f2}

H~2~ Inhibits LPS-Induced Inflammatory Cytokines Production {#s3_3}
-----------------------------------------------------------

As the ligand of pattern recognition receptor (PRR) TLR4, LPS can induce various inflammatory cytokines production ([@B66]). Among these cytokines**,** TNFα, IL-1β, and IL-18 have been reported to result in cardiac dysfunction ([@B24]; [@B42]; [@B14]; [@B35]). As previous studies ([@B24]; [@B42]; [@B14]; [@B15]; [@B35]), LPS increases the protein levels of TNFα, IL-1β, and IL-18 in serum ([**Figures 3A--C**](#f3){ref-type="fig"}) and enhanced the mRNA levels of TNFα, IL-1β, and IL-18 in H9c2 cardiomyocytes ([**Figures 3D--F**](#f3){ref-type="fig"}). These increased TNFα, IL-1β, and IL-18 can be suppressed by pretreatment of intraperitoneal injection of H~2~ *in vivo* ([**Figures 3A--C**](#f3){ref-type="fig"}) and pretreatment of H~2~-rich medium *in vitro* ([**Figures 3D--F**](#f3){ref-type="fig"}). Therefore, these results indicate that H~2~ inhibits the expression of inflammatory cytokines in serum and cardiomyocytes during sepsis-induced cardiomyopathy.

![The effects of H~2~ on LPS-induced inflammatory cytokines expression. **(A--C)** The concentration of TNFα, IL-18, and IL-1β in serum (*n* = 5--8). \*\**p* \< 0.01 vs Control, ^\#^ *p* \< 0.05 vs LPS, ^\#\#^ *p* \< 0.01 vs LPS. **(D--F)** Quantification of the mRNA levels of TNFα, IL-18, and IL-1β in H9c2 cardiomyocytes, GAPDH was used as a loading control (*n* = 3). \**p* \< 0.05 vs Control, \*\**p* \< 0.01 vs Control, ^\#\#^ *p* \< 0.01 vs LPS. n.s. means "no significance."](fphar-10-00865-g003){#f3}

H~2~ suppresses TLR4-Mediated Innate Immune signaling {#s3_4}
-----------------------------------------------------

The increased cytokines previously discussed in LPS-challenged mice or in H9c2 cardiomyocytes are primarily induced by TLR4-mediated innate immune signaling, such as TRAF6-TAK1-IKKβ-NF-κB and TRAF6-MAPK-AP-1 signaling ([@B66]). Thus, we investigate whether the inhibition of H~2~ on LPS-induced inflammatory cytokines production is related to TLR4-mediated innate immune signaling in cardiomyocytes. The immunoblotting indicated that the increased phosphorylation of p38MAPK, JNK1/2, and ERK1/2 ([**Figures 4A--F**](#f4){ref-type="fig"}) and the nuclear translocation of NF-κB ([**Figures 5A, B**](#f5){ref-type="fig"}) by LPS were suppressed by H~2~ *in vivo* and *in vitro*. Moreover, the expression of TLR4 was increased after LPS stimulation, which was also blocked by H~2~ *in vivo* and *in vitro* ([**Figures 6A, B**](#f6){ref-type="fig"}). Collectively, TLR4-mediated innate immune signaling in cardiomyocytes can be inhibited by H~2~ *in vivo* and *in vitro.*

![The effects of H~2~ on LPS-mediated MAPK signaling activation. Representative Western blot and quantification of p38 phosphorylation **(A** and **D)**, JNK phosphorylation **(B** and **E)**, and ERK1/2 phosphorylation **(C** and **F)** to their total protein expressions (*n* = 3). \**p* \< 0.05 vs Control, \*\**p* \< 0.01 vs Control, ^\#^ *p* \< 0.05 vs LPS, ^\#\#^ *p* \< 0.01 vs LPS.](fphar-10-00865-g004){#f4}

![The effects of H~2~ on LPS-mediated nuclear translocation of NF-κB. Representative Western blot and quantification of nuclear NF-κB to Histone H3 *in vivo* **(A)** and *in vitro* **(B)**, respectively (*n* = 4). \*\**p* \< 0.01 vs Control, ^\#\#^ *p* \< 0.01 vs LPS.](fphar-10-00865-g005){#f5}

![The effects of H~2~ on LPS-induced TLR4 expression. Representative Western blot and quantification of TLR4 to GAPDH *in vivo* **(A)** and *in vitro* **(B)**, respectively (*n* = 4). \*\**p* \< 0.01 vs Control, ^\#\#^ *p* \< 0.01 vs LPS.](fphar-10-00865-g006){#f6}

Discussion {#s4}
==========

The current studies were initiated to determine the effect of H~2~ intraperitoneal injection on LPS-induced cardiac dysfunction and its immune mechanism. We find that H~2~ protects against LPS-induced cardiac dysfunction *via* blocking TLR4 signaling-mediated cytokines expression.

Being traditionally recognized as a biologically inert gas, recent studies suggest that H~2~ can act as a biomolecule and has the potential ability to inhibit oxidative stress, inflammation, and apoptosis, thus, manifests cardioprotective effects or safeguards against tissue injury ([@B36]; [@B37]; [@B69]). Supplements of exogenous H~2~ by inhalation or intraperitoneal injection of H~2~-rich saline attenuates myocardial ischemia/reperfusion (I/R) injury and improves cardiac function through anti-oxidative, anti-apoptotic, and anti-inflammatory effects ([@B21]; [@B49]; [@B68]). Our previous studies indicated that H~2~ protects against isoproterenol (ISO)-induced cardiac dysfunction and cardiomyocyte hypertrophy *in vivo* or *in vitro* ([@B70]; [@B67]). *Akiko Noda* group indicated that chronic H~2~ inhalation prevents left ventricular hypertrophy in hypertensive Dahl salt-sensitive rats ([@B31]). We reveled that H~2~ protects against LPS-induced cardiac dysfunction.

LPS (1 μg/ml) can upregulate pathologic hypertrophy marker ANP and BNP in H9c2 cardiomyocytes from 2 to 24 h and induce cellular hypertrophy in 3, 6, 12, and 24 h through calcineurin/NFAT-3 signaling pathway in H9c2 cardiomyocytes ([@B28]). In our study, H~2~-rich medium inhibits the upregulation of ANP and BNP by LPS *in vitro*. Left ventricular wall edema occurred during sepsis ([@B47]; [@B6]), and LPS induced enlargement in the cell size of cardiomyocytes *in vivo* ([@B55]). In our study, left and right ventricular cavities were enlarged by LPS, LPS decreased the thickness of interventricular septum, and these phenotypes were improved by H~2~. The LV mass AW and LV mass AW (Corrected) were slight increased by LPS, and H~2~ decreases the upregulation of LV mass AW and LV mass AW (Corrected), although there were no statistical differences between groups. Drosatos et al. has also revealed that heart:body weight and lung:body weight ratios were not increased by LPS ([@B15]). The animal strains, animal sources, feeding environment, and the batch and dosage of LPS used might be responsible for these differences.

The endogenous H~2~ is produced by the bacterial species present in human gut, mouth and pharynx, the respiratory system, vagina, and skin ([@B37]). Thus, given antibiotics for 4 days by mixing penicillin and streptomycin in the drinking water can reduce the H~2~ concentration below the 1-ppm detection limit in the expired air of male C57BL/6J mice, and the infarct size was significantly higher in mice administered with antibiotics than that in antibiotics non-treated mice ([@B46]). Another clinical investigation recently revealed overnight change in H~2~ concentration (ΔH~2~) was significantly lower in patients with chronic heart failure compared with controls and was positively correlated with cardiac index ([@B45]). Ostojic also proposed an idea that an impaired production of endogenous H~2~ by intestinal microbiota might play a role in Parkinson disease pathogenesis ([@B38]). The key question that needs to be resolved is what is the function of the endogenous H~2~ in cardiovascular homeostasis and whether the endogenous H~2~ levels are related to the individual difference in the resistance of sepsis-induced cardiomyopathy.

LPS, a natural ligand for TLR4, induces cardiac inflammation and left ventricular dysfunction ([@B24]; [@B14]; [@B15]). TLR4 also contributes to the development of cardiac remodeling following pressure overload, myocardial infarction, angiotensin II, or ISO infusion *in vivo* ([@B17]; [@B53]; [@B8]; [@B12]; [@B18]; [@B23]). Therefore, blocking TLR4-related innate immune signaling can improve the previously discussed stimuli-mediated cardiac dysfunction. H~2~ has been shown to improve LPS-induced lung ([@B41]; [@B27]; [@B60]; [@B19]; [@B29]; [@B13]), liver ([@B48]; [@B22]), and bowel ([@B44]) injuries. Herein, we showed that H~2~ inhibited LPS-mediated cardiac dysfunction, which can be induced by LPS and LPS-induced many kinds of cytokines, such as TNFα, IL-1β, and IL-18 ([@B52]; [@B3]; [@B25]; [@B5]; [@B51]; [@B28]; [@B59]; [@B7]; [@B15]; [@B35]). These increased cytokines by LPS can be produced by inflammatory cells and by the cardiomyocytes and fibroblasts ([@B32]; [@B9]; [@B1]; [@B2]). In our study, we have shown that H~2~-rich medium reduced the mRNA levels of TNFα, IL-1β, and IL-18 in LPS-challenged H9c2 cardiomyocyte. The increased protein levels of TNFα, IL-1β, and IL-18 in the serum by LPS were also decreased after H~2~ pretreatment *in vivo*. Similar to our results, using different H~2~ delivery methods, *Atsunori Nakao* group and others have also indicated that H~2~ can decrease these pro-inflammatory cytokine levels in the target tissue or in serum in LPS-induced bowel dysfunction (LPS: 15 mg/kg) ([@B44]) or acute lung injury \[LPS: 25 μg/mouse ([@B60]) or 15 mg/kg ([@B27])\] or GalN/LPS-induced acute liver injury (LPS: 20 μg/kg) ([@B48]). However, if the dose of LPS increases to 30 mg/kg, H~2~ does not markedly ameliorate an elevation in inflammatory cytokines ([@B22]). Therefore, the severity of disease is essential for the effects of H~2~; moreover, the dose of H~2~ used is also important.

It is well established that NF-κB and AP-1 are mainly responsible for TLR4 to induce the production of pro-inflammatory cytokines, such as TNFα, IL-1β, and IL-18 ([@B66]; [@B71]). The nuclear translocation of NF-κB and the phosphorylation of AP-1 upstream kinases ERK1/2, p38MAPK, and JNK by LPS in the heart are suppressed by H~2~. The suppression of H~2~ on NF-κB and MAPK exists widely in many kinds of animal models, such as isoproterenol-induced cardiac hypertrophy ([@B70]), LPS-induced acute lung injury ([@B60]), and intimal hyperplasia in arterialized vein grafts ([@B50]). Besides TLR4 signaling activation, LPS also enhanced TLR4 expression ([@B16]), and the increased TLR4 was blocked by H~2~ in cardiomyocytes. However, the precise molecular targets of H~2~ in TLR4-mediated innate immune signaling still need further investigation.

Conclusion {#s5}
==========

H~2~ protects against LPS-induced cardiac dysfunction *via* suppressing the excessive production of pro-inflammatory cytokines in the parenchymal cells of the heart by blocking TLR4-MAPKs/NF-κB signaling. Therefore, H~2~ is a promising natural agent for the prevention of LPS-induced cardiac dysfunction.
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